GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic  alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.

GlaxoSmithKline PLC

Ms. Emma Natasha Walmsley

CEO & Director

Ms. Julie Belita Brown A.C.A.

CFO & Executive Director

Ms. Shobie  Ramakrishnan

Chief Digital & Technology Officer

Mr. Tony  Wood

Chief Scientific Officer and Head of R&D

Ms. Sarah  Elton-Farr

Head of Investor Relations

Mr. James  Ford

Senior VP & Group General Counsel of Legal & Compliance

Ms. Sally  Jackson

Senior Vice President of Global Communications & CEO Office

Mr. David Simon Redfern BSc (Hons), CA

President of Corporate Development

Ms. Diana  Conrad

Chief People Officer

Mr. Philip C. Thomson

President of Global Affairs

GSK's next earnings is on February 5, 2025 (Before Market Open)

GSK's latest dividend is 0.15 GBP on August 15, 2024

GlaxoSmithKline PLC (GSK) Stock Analysis, Discussion Forum and Financial Metrics - LSE Exchange

GlaxoSmithKline PLC (GSK) Earnings Report Date and History | LSE

GSK's next earnings is on February 5, 2025 (Before Market Open)

When is the earnings report for GSK?

GSK Earnings History

GSK's latest dividend is 0.15 GBP on August 15, 2024

GSK Stock Discussion Forum and Message Board

News for LSE: GSK